PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion

Tseng, Yu Ting; Ho, Hsiang‐Ling; Lai, Chiung Ru; Luo, Yung‐Hung; Tseng, Yen Chiang; Whang‐Peng, Jacqueline; Lin, Yi; Chou, Teh Ying; Chen, Yuh Min

doi:10.1016/j.jtho.2017.10.034

Cited by 38 publications

(31 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also found that low PD‐L1 expression in immune cells is associated with poor patients’ survival. They finally suggested that MPE could be used for PDL‐1 testing . A French group evaluated PD‐L1 tumour proportion score using 22C3 anti‐PD‐L1 antibody‐based laboratory developed tests (LDTs), from 70 paired biopsy and cytology samples including 30 samples from MPE.…”

Section: Implications Of New Therapies In Nsclcmentioning

confidence: 99%

“…A part from PDL1 expression, other biomarkers, such as tumour mutational burden (TMB) are emerging to predict the response to immunotherapy, and it would be interesting to determine whether MPE can be a tool, especially when there is no tumour tissue available.…”

Section: Implications Of New Therapies In Nsclcmentioning

confidence: 99%

“…18 The correlation of PD-L1 expression of the tumour invading the pleura and inflammatory cells from the effusion is unclear. Tseng et al 19 analysed IHC staining for PDL1 in tumour cells, immune cells and macrophages of cellblock specimen from MPE of lung cancer patients. They found that PD-L1 expression of MPE tumour cells were significantly associated with PD-L1 expression of macrophages and immune cells, suggesting that there might be an immune interaction between tumour cells and macrophages in MPE.…”

Section: Immunotherapy/immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…They finally suggested that MPE could be used for PDL-1 testing. 19 A French group 20 evaluated PD-L1 tumour proportion score using 22C3 anti-PD-L1 antibody-based laboratory developed tests (LDTs), from 70 paired biopsy and cytology samples including 30 samples from MPE. Their results support the use of this technique to evaluate PD-L1 expression in cytology samples including MPE samples.…”

Section: Immunotherapy/immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…In this study, 89/201 (44.3%) patients had MPE which did not correlate with a shorter progression-free survival (PFS) in patients with nivolumab. 24 A part from PDL1 expression, other biomarkers, such as tumour mutational burden (TMB) are emerging to predict the response to immunotherapy, 19 and it would be interesting to determine whether MPE can be a tool, especially when there is no tumour tissue available.…”

Section: Immunotherapy/immune Checkpoint Inhibitorsmentioning

confidence: 99%

See 4 more Smart Citations

Novel insights into the systemic treatment of lung cancer malignant pleural effusion

Tissot

Gay

Brun

et al. 2019

Clinical Respiratory J

View full text Add to dashboard Cite

Lung cancer is the most common fatal malignancy worldwide. Approximately 75% of non‐small‐cell lung cancer (NSCLC) patients are diagnosed at an advanced or a metastatic stage. Since 2007, NSCLC patients with malignant pleural effusion (MPE) are staged as M1 disease. During the last decades, chemotherapeutic agents failed to offer a significant improvement of survival in patients with metastatic disease. The current review aims to summarize the actual situation of the recently developed therapies in patients with lung cancer and MPE.

show abstract

Section: Implications Of New Therapies In Nsclcmentioning

confidence: 99%

Section: Implications Of New Therapies In Nsclcmentioning

confidence: 99%

Section: Immunotherapy/immune Checkpoint Inhibitorsmentioning

confidence: 99%

Section: Immunotherapy/immune Checkpoint Inhibitorsmentioning

confidence: 99%

Section: Immunotherapy/immune Checkpoint Inhibitorsmentioning

confidence: 99%

See 3 more Smart Citations

Novel insights into the systemic treatment of lung cancer malignant pleural effusion

Tissot

Gay

Brun

et al. 2019

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

Ancillary Studies for Serous Fluids

Bubendorf¹,

Firat²,

Kulaç

et al. 2020

The International System for Serous Fluid Cytopathology

View full text Add to dashboard Cite

The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer

Lin

Yuan

et al. 2020

Cancer Immunol Immunother

View full text Add to dashboard Cite

Background Malignant pleural effusion (MPE)-macrophage (Mφ) of lung cancer patients within unique M1/M2 spectrum showed plasticity in M1–M2 transition. The M1/M2 features of MPE-Mφ and their significance to patient outcomes need to be clarified; furthermore, whether M1-repolarization could benefit treatment remains unclear. Methods Total 147 stage-IV lung adenocarcinoma patients undergoing MPE drainage were enrolled for profiling and validation of their M1/M2 spectrum. In addition, the MPE-Mφ signature on overall patient survival was analyzed. The impact of the M1-polarization strategy of patient-derived MPE-Mφ on anti-cancer activity was examined. Results We found that MPE-Mφ expressed both traditional M1 (HLA-DRA) and M2 (CD163) markers and showed a wide range of M1/M2 spectrum. Most of the MPE-Mφ displayed diverse PD-L1 expression patterns, while the low PD-L1 expression group was correlated with higher levels of IL-10. Among these markers, we identified a novel two-gene MPE-Mφ signature, IL-1β and TGF-β1, representing the M1/M2 tendency, which showed a strong predictive power in patient outcomes in our MPE-Mφ patient cohort (N = 60, p = 0.013) and The Cancer Genome Atlas Lung Adenocarcinoma dataset (N = 478, p < 0.0001). Significantly, β-glucan worked synergistically with IFN-γ to reverse the risk signature by repolarizing the MPE-Mφ toward the M1 pattern, enhancing anti-cancer activity. Conclusions We identified MPE-Mφ on the M1/M2 spectrum and plasticity and described a two-gene M1/M2 signature that could predict the outcome of late-stage lung cancer patients. In addition, we found that “re-education” of these MPE-Mφ toward anti-cancer M1 macrophages using clinically applicable strategies may overcome tumor immune escape and benefit anti-cancer therapies.

show abstract

PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion

Abstract: These results suggest that there might be an immune interaction between pleural effusion tumor cells and macrophages. The low intensity of PD-L1 expression in immune cells is associated with the poor survival of patients with lung cancer with malignant pleural effusion.

Cited by 38 publications

References 14 publications

Novel insights into the systemic treatment of lung cancer malignant pleural effusion

Novel insights into the systemic treatment of lung cancer malignant pleural effusion

Ancillary Studies for Serous Fluids

The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer

Contact Info

Product

Resources

About